{"gao_id": "GAO-19-630", "published": "2019-09-09T12:00:00Z", "released": "2019-09-09T08:00:00Z", "summary": "Can patients with life-threatening diseases get access to an unapproved drug if they can't participate in a drug study? If the drug manufacturer agrees, patients may access an unapproved drug through FDA\u2019s expanded access program or through the federal Right-to-Try law. Most of the drug manufacturers in our review were willing to consider individual requests from patients to access their unapproved drugs, according to the...", "title": "Investigational Drugs: FDA and Drug Manufacturers Have Ongoing Efforts to Facilitate Access for Some Patients", "topics": ["Informed consent", "Informed consent (medical law)", "Clinical trials", "Cancer", "Testing", "Physicians", "Adverse events", "Drugs", "Eligibility criteria", "Health Care", "Patient care"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-19-630", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-19-630-highlights.pdf"}, {"title": "Full Report (33 pages)", "url": "https://www.gao.gov/assets/gao-19-630.pdf"}, {"title": "Accessible PDF (35 pages)", "url": "https://www.gao.gov/assets/710/701386.pdf"}]}